UCB S.A.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia,...
Latest News
29 days ago · seekingalpha.com
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology TranscriptUCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
1 month ago · seekingalpha.com
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series TranscriptUCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
1 month ago · seekingalpha.com
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 TranscriptUCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2 months ago · zacks.com
UCB (UCBJY) Upgraded to Buy: Here's WhyUCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago · zacks.com
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersTrump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
3 months ago · seekingalpha.com
UCB SA (UCBJY) Q2 2026 Earnings Call TranscriptUCB SA (UCBJY) Q2 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove UCBJY